Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05048797
Title A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors AstraZeneca
Indications

lung non-squamous non-small cell carcinoma

Therapies

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Trastuzumab deruxtecan

Age Groups: senior
Covered Countries USA

Additional content available in CKB BOOST